公开(公告)号：US20230116062A1

公开(公告)日：2023-04-13

申请号：US17898776

申请日：2022-08-30

申请人： CASE WESTERN RESERVE UNIVERSITY ,  BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： Sanford Markowitz ,  Amar Desai ,  Joseph Ready

IPC分类号： A61K31/4365 ,  A61K38/19 ,  A61K31/495 ,  A61K31/444 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/519 ,  A61K31/496

摘要： A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.

公开(公告)号：US20230113413A1

公开(公告)日：2023-04-13

申请号：US17818687

申请日：2022-08-09

申请人： Nektar Therapeutics

发明人： J. Milton Harris ,  Antoni Kozlowski ,  Samuel P. McManus ,  Michael D. Bentley ,  Stephen A. Charles

IPC分类号： A61K47/60 ,  A61K31/52 ,  A61K38/095 ,  C08G65/329 ,  C08G65/333 ,  A61K31/357 ,  A61K31/4025 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/24 ,  A61K38/27 ,  A61K38/37

摘要： Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.

公开(公告)号：US20230094423A1

公开(公告)日：2023-03-30

申请号：US17787228

申请日：2020-12-16

申请人： Cella Therapeutics, LLC

发明人： Rhett M. Schiffman ,  Lukas Scheibler

IPC分类号： A61K38/18 ,  A61K38/19 ,  A61K31/357 ,  A61K9/00 ,  A61P27/02

摘要： This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, a cysteine-aspartic protease inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

公开(公告)号：US11602579B2

公开(公告)日：2023-03-14

申请号：US16137396

申请日：2018-09-20

申请人： NOVADIP BIOSCIENCES

发明人： Denis Dufrane

IPC分类号： A61K35/28 ,  A61K38/30 ,  A61L27/36 ,  A61L27/10 ,  A61K38/18 ,  A61P19/08 ,  A61K38/19 ,  A61L27/12 ,  A61L27/54 ,  C12N5/077 ,  A61L27/38 ,  A61K38/17 ,  A61L27/46

摘要： The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1α). The present invention also relates to methods for producing the biomaterial and uses thereof.

公开(公告)号：US11602546B2

公开(公告)日：2023-03-14

申请号：US16347581

申请日：2017-09-25

申请人： YEDÍTEPE ÜNÍVERSÍTESÍ

发明人： Fatih Kocabas ,  Raife Dilek Turan

IPC分类号： A61K35/28 ,  A61K31/095 ,  A61K31/655 ,  A61K38/18 ,  A61K38/19 ,  A61K38/28 ,  A61K38/38 ,  A61K38/40 ,  A61K31/15 ,  A61K31/167

摘要： A composition inhibiting MEIS proteins. The MEIS proteins are effective in proliferation of hematopoietic stem cells. A formulation capable of easily passing through the cell membrane and perform its activity in the cell, and can inhibit MEIS activity in a dose dependent manner. The combination includes isolated cells, medium, growth factors and MEISi inhibitor. The isolated cells are isolated from mouse bone marrow, human bone marrow and human umbilical cord blood. The medium has a pH value of 7.2 and contains bovine serum albumin, recombinant insulin, transferrin, 2-mercaptoethanol and IMDM medium. The growth factors are hematopoietic stem cell factor SCF, fetus liver tyrosine kinase-3 ligand Flt3L, and thrombopoietin. A chemical formula of the MEISi-1 is 4-[2-(benzylamino)-2-oxoethoxy]-N-(2,3-dimethylphenyl) benzamide. A chemical formula of MEISi-2 is 4-hydroxy-N′-[(Z)-(2-oxonaphthalen-1-ylidene)methyl] benzohydrazide.

公开(公告)号：US20230056721A1

公开(公告)日：2023-02-23

申请号：US17963607

申请日：2022-10-11

申请人： Aerovate Therapeutics, Inc.

发明人： Ben Dake ,  Ralph Niven

IPC分类号： A61K31/506 ,  A61K9/00 ,  A61K31/501 ,  A61K38/19 ,  A61K47/26 ,  A61P9/12 ,  A61P11/00 ,  A61K38/18

摘要： The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.

公开(公告)号：US11564998B2

公开(公告)日：2023-01-31

申请号：US16577734

申请日：2019-09-20

申请人： ModernaTX, Inc.

发明人： Antonin De Fougerolles ,  Justin Guild

IPC分类号： A61K48/00 ,  C12N15/85 ,  C07K14/47 ,  C12N9/64 ,  C07K14/62 ,  A61K31/7115 ,  C12N9/88 ,  A61K9/127 ,  C12N15/11 ,  C07K14/705 ,  C07K14/505 ,  C07K14/535 ,  C12N9/10 ,  C12N9/00 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C07K14/005 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  A61K38/17 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07H21/02 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K47/54 ,  A61K9/14 ,  A61K9/51 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/48 ,  C07K14/515 ,  C07K16/00 ,  A61K38/00

摘要： The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US11541175B2

公开(公告)日：2023-01-03

申请号：US17090615

申请日：2020-11-05

申请人： P&X Medical NV

发明人： Peter Wostyn

IPC分类号： A61M5/172 ,  A61K38/19 ,  A61K35/30 ,  A61K9/00 ,  A61M27/00 ,  A61M5/142 ,  A61P27/06 ,  G16H40/67 ,  G16H20/17 ,  G16H50/20 ,  G16H40/63

摘要： Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.

公开(公告)号：US20220409697A1

公开(公告)日：2022-12-29

申请号：US17769916

申请日：2020-10-19

申请人： RAMEA LLC ,  Extend Biosciences Inc.

发明人： Russell J. Barron ,  Tarik Soliman ,  Daniel B. Hall

IPC分类号： A61K38/19 ,  A61K47/55

摘要： The invention provides non-hormonal Vitamin D conjugated to G-CSF or compounds with G-CSF activity or GM-CSF or compounds having GM-CSF activity singly or in combination that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.

公开(公告)号：US20220409527A1

公开(公告)日：2022-12-29

申请号：US17787672

申请日：2021-01-21

申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Charles S. SFEIR

IPC分类号： A61K9/00 ,  C07K16/24 ,  A61K38/19 ,  A61P1/02 ,  A61K9/16

摘要： The present invention relates to systems and methods for the treatment of conditions of chronic inflammation, such as periodontitis, that includes the use of sustained release microparticles to locally deliver a compound or agent to reduce inflammation of tissue, such as periodontal tissue, and/or inflammatory mediators. The microparticles are loaded with a compound or agent selected from the group consisting of C-C motif chemokine ligand 2 (CCL2), interleukin 4 (IL-4), anti-interleukin 17 (IL17 antibody), and mixtures or blends thereof